The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms

Cancer Research

Volumn 68, Issue 8, 2008, Pages 2745-2754

  Felicetti, Federica ^a   Errico, M Cristina ^a   Bottero, Lisabianca ^a   Segnalini, Patrizia ^a   Stoppacciaro, Antonella ^b   Biffoni, Mauro ^a   Felli, Nadia ^a   Mattia, Gianfranco ^a   Petrini, Marina ^a   Colombo, Mario P ^c   Peschle, Cesare ^a   Carè, Alessandra ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; CARCINOGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; PROMYELOCYTIC LEUKEMIA PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLOGY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; ZINC FINGERS;

EID: 42349087828     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2538     Document Type: Article

References (40)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new target therapy. Nature 2007;445:851-7.
2. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355:51-65.
3. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 1998;17:4358-69.
4. Dhomen N, Marais R. New insight into BRAF mutation in cancer. Curr Opin Genet Dev 2007;17:31-9.
5. Clark WH, Elder DE, Guerry D IV, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesion of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-65.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
8. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54.
9. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102:19075-80.
10. Ciafrè SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNA in primary glioblastoma. Biochem Biophys Res Commun 2005;334:1351-8.
11. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3699-708.
12. Galardi S, Mercatelli N, Giorda E, et al. MiR-221 and miR-222 expression affects the proliferation potencial of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 2007;282:23716-24.
13. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005;102:18081-6.
14. Alexeev V, Yoon K. Distinctive role of the c-kit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006;126:1102-10.
15. Felicetti F, Bottero L, Felli N, et al. Role of PLZF in melanoma progression. Oncogene 2004;3:4567-76.
16. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with "antagomirs". Nature 2005;438:685-9.
17. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-8.
18. Zhou X, Ruan J, Wang G, Zhang W. Characterization and identification of microRNA core promoters in four model species. PLoS Comput Biol 2007;3:412-23.
19. Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell 2005;123:819-31.
20. Labbaye C, Quaranta MT, Pagliuca A, et al. PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene 2002;21:6669-79.
21. Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;108:3068-71.
22. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-kit signalling in melanocytes. Nature 1998;391:298-301.
23. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006;12:406-14.
24. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22:3087-91.
25. Li W, Sanki A, Karim RZ, et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006;38:287-01.
26. Tchernev G, Orfanos CE. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol 2007;34:247-56.
27. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inihibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998;153:305-12.
28. Ivan D, Diwan AH, Esteva FJ, Prieto VG. Expression of cell cycle p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol 2004;17:811-8.
29. Kotoshiba S, Kamura T, Hara T, Ishida N, Nakayama KI. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem 2005;280:17694-700.
30. Delmas C, Aragou N, Poussard S, Cottin P, Darbon JM, Manenti S. MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells. Requirement of p27Kip1 nuclear export. J Biol Chem 2003;278:12443-51.
31. Koff A. How to decrease p27Kip1 levels during tumor development. Cancer Cell 2006;9:75-6.
32. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007;100:1164-73.
33. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003;199:275-88.
34. Goding C, Meyskens FL. Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. Clin Cancer Res 2006;12:1069-73.
35. Price ER, Ding H-F, Badalian T, et al. Lineage-specific signaling in melanocytes. J Biol Chem 1998;273:17983-6.
36. Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI. Role of microphthalmia transcription factor (Mitf ) in melanoma differentiation. Biochem Biophys Res Commun 2007;354:830-5.
37. Carreira S, Goodall J, Denat L, et al. Mitf regulation of Dia 1 controls melanoma proliferation and invasiveness. Genes Dev 2006;20:3426-39.
38. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005;170:703-8.
39. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007;17:3-7.
40. Wolchok JD, Saenger YM. Current topics in melanoma. Curr Opin Oncol 2007;19:116-20.